Bone marrow-derived cells contribute to a wide variety of normal tissues such as liver, brain, and heart. This is due, at least in part, to cell fusion, in some cases with macrophages. [1] [2] [3] [4] [5] [6] There are more than 25 reports of tumor hybridization in animals, 7 and myeloid cell-tumor hybrids have been observed in melanoma, 8 lymphoma, 9 sarcoma, 10, 11 and insulinoma models. 12 In some cases, tumor hybridization was associated with metastasis. 7 However, little is known of this in humans. Recently, the first genetic evidence for bone marrow-tumor cell hybridization in humans was reported. 13 In that study, tumor DNA was analyzed from a child who developed metastatic renal cell carcinoma during a time when he had also received a BMT from his cancer-free, 6-year-old brother. Microdissected tumor cells of a nodal metastasis were shown through PCR to contain donor DNA, consistent with BMT-tumor hybridization.
In the case herein, a primary renal cell carcinoma was probed from a female patient who, 2 years prior to detection of the tumor, had received a BMT from her 15-year-old son. Due to the male donor-female recipient nature of the BMT, FISH could be used to search for putative BMT-tumor hybrids. Karyotyping revealed that the tumor contained a clonal trisomy 17. Combining H&E staining and dual-label FISH, the donor Y and three or more copies of chromosome 17 were visualized together in individual nuclei of carcinoma cells, providing direct genetic and morphological evidence for BMT-tumor hybrids.
The patient presented in 1987 at the age of 32 with cervical lymphadenopathy 6 weeks after the birth of her son. A lymph node biopsy showed small lymphocytic lymphoma (SLL/CLL). A bone marrow aspirate was positive, and karyotyping revealed numerous clonal complex cytogenetic abnormalites involving rearrangements of chromosomes 1, 2, 3, 4, 5, 8, 15, and 16. She underwent a series of treatments including chemotherapy and wholebody radiation. Following further relapse, she received an allogeneic stem cell transplant from her nine of 10 antigenmatched son with the use of reduced-intensity conditioning. She experienced slow resolution of lymphadenopathy and bone marrow infiltration over the next several months. At 1 year, restaging bone marrow studies and CT scans showed no evidence of disease. The post transplant course was complicated by mild chronic graft-versus-host disease treated with low-dose steroids, hydroxycloroquine, and tacrolimus. The most recent FISH studies of the bone marrow, 2 years after transplant and about 6 months before diagnosis of the renal cell carcinoma showed that 99.6% (700 of 703) of the cells displayed an XY signal pattern, with no abnormalities and a karyotype of 46 XY. Surveillance CT scans showed no evidence of disease but did show a suspicious left renal lesion 2 years after transplant. She underwent a partial renal resection that showed a renal cell carcinoma. The pathology diagnosis was 'papillary carcinoma (1.2 cm in greatest dimension) with oncocytic features'. She remains without evidence of lymphoma and has an excellent performance status 31 months after transplant.
For karyotyping, a fresh piece of the surgically removed tumor was disaggregated with collagenase, placed into monolayer culture, and incubated with colcemid to obtain metaphase cells. Tumor sections (4 mm) were deparaffinized by two incubations in xylene (10 min each), dehydrated in ethanol (5 min), and air-dried. Slides were incubated in sodium thiocyanate (1 M in H 2 O, 801C, 20 min), washed with H 2 O, washed with 2 Â saline sodium citrate (SSC, 3 min) (1 Â SSC is 0.15 M sodium chloride and 0.015 M sodium citrate), and air-dried. Slides were then incubated with pepsin (Sigma, P-7012; 4 mg/ml in 0.9% NaCl, 371, 20 min), washed with water, rinsed in 2 Â SSC (3 min), air-dried, and then incubated in ethanol (10 min). Denaturation was performed in 70% formamide, 2 Â SSC (15 min, 801C), then slides were rinsed with 70% ethanol (3 min), and air-dried. Directly labeled fluorescent probes specific to the pericentromeric regions of chromosomes Y, 11, 14, and 17 (CEP probes) were from Vysis (Downers Grove, IL, USA). Hybridization and slides washing procedures were according to the manufacturer's protocol. Samples were evaluated and images were captured using an Olympus BX60 fluorescence microscope (Olympus, Melville, CA, USA), with filters including DAPI single-bandpass, Spectrum Orange single-bandpass, Spectrum Green single-bandpass, and Red/Green dual-bandpass, and analyzed using image analysis software (CytoVision, Applied Imaging Corp.,Santa Clara, CA, USA). Nuclei with poor hybridization, over digestion, or overlaps were excluded. To estimate the percentage of tumor cells exhibiting a particular tumor marker, or combination of markers, at least 50 high-power fields (B1000 cells total) were counted. (b) Colocalization of FISH images (right) with stored images of the same field of primary renal carcinoma cells previously stained with H&E (left). Individual panels are described in the text. Fields of interest were photographed, and the images were matched with stored images of fields from the same slide previously stained with H&E. In the H&E-stained sections, carcinoma cells were distinguished from normal cells by their large size, polygonal shape, abundant granular eosinophilic cytoplasm, and round or ovoid nuclei, usually located centrally, with fine chromatin. Verification of carcinoma cells was by pathologists, including co-author RL. Asterisks (*) denote nuclei containing a trisomy 17. Y chromosome: red; chromosome 17: green.
We searched formalin-fixed histology specimens for cells containing both the Y, as a BMT cell marker, and three or more 17's, as a tumor cell marker. Such cells were readily found in a region covering about 10% of the tumor area, located adjacent to normal renal tissue, where about 1% of the cells contained both markers. Examples are shown (Figure 2a . As a control, tumor sections were also surveyed for chromosomes 4 and 11. Only normal complements of these chromosomes were observed, with no trisomies or other hyperploidies in the 1000 cells surveyed for each (not shown). We identified more than 50 cells containing a Y together with a trisomy, or in two cases a tetrasomy, 17 (Figure 2a, panel  22) . Interestingly, gains in 17 are highly associated with papillary renal cell carcinoma (prcc), and thus consistent with the histopathology diagnosis in our case.
14 If the Y-trisomy 17 cells were hybrids, why did not more of them show a pentasomy 17, with two copies coming from the BMT donor and three from the recipient? Although this question could not be addressed in the case herein, an answer may stem from earlier studies with experimental hybrids where chromosome reduction mechanisms were described. Fusion of cells is known to result in destabilization of chromosomes, and selection for restabilization by extrusion of extra chromosomes has been reported in somatic cell hybrids, and in cells destabilized by aneuploidy and gene amplification. 15 We conclude that the data best fit the clinical and pathological diagnoses that the tumor arose de novo in the patient, and that the Y-trisomy/tetrasomy 17 cells, and probably other Y-containing carcinoma cells, were hybrids (Figure 1 ). That chromosomal aberrations can occur in donor cells following BMT was recently demonstrated in a case involving severe congenital aplastic anemia, where BMT cells in the recipient (but not the donor) displayed a monosomy 7. 16 Thus, in principle, the tumor karyotype could have been generated in our case during differentiation of BMT cells into prcc cells. However, it seems far more likely that the tumor arose de novo in the recipient due to prior treatment, including the known risk factors of radiation (administered several years preceding the BMT), and immunosuppression.
In summary, we identified BMT donor Y chromosomes in tumor cells of a papillary renal cell carcinoma from a female recipient. Thus, donor BMT cells, or at least chromosomes, had in some manner engrafted into the tumor and acquired the histopathology and cytogenetics of a primary prcc. Though we favor fusion hybridization with pre-existing tumor cells as the most probable mechanism, other possibilities remain, such as transfer of cryptic carcinoma cells from the donor, or differentiation of BMT cells into carcinoma cells without fusion. However, there is precedent for tumor hybridization in animals, [7] [8] [9] [10] [11] [12] and recently in a case of human renal cell carcinoma, 13 and several reports have linked myeloid cell-tumor cell hybridization with increased metastatic potential. 7 Macrophagesomatic cell fusion has also been reported in liver regeneration and other systems in mice. [1] [2] [3] [4] [5] [6] That bone marrow-tumor hybrids now appear to exist in at least some human carcinomas suggests that tumor hybridization merits renewed consideration as a potential factor in human metastasis. Continued analyses of malignancies in BMT recipients should be a fruitful approach to these questions. 
